Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells

Virology Journal

Volumn 8, Issue , 2011, Pages

  Yao, Luyu ^a   Yan, Xiaobo ^c   Dong, Huijia ^b   Nelson, David R ^a   Liu, Chen ^b   Li, Xiaoyu ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROTAMOXIFEN; ALPHA INTERFERON; BETA INTERFERON; ESTROGEN RECEPTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN M; INTERFERON REGULATORY FACTOR 3; RETINOIC ACID INDUCIBLE PROTEIN I; STAT PROTEIN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG; DDX58 PROTEIN, HUMAN; DEAD BOX PROTEIN; HYBRID PROTEIN;

ARTICLE; CELL LINE; DIMERIZATION; HEPATITIS C; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; INTERNAL RIBOSOME ENTRY SITE; PROTEIN EXPRESSION; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPATITIS C VIRUS; IMMUNOLOGY; LIVER CELL; MOUSE; PHYSIOLOGY; PROTEIN MULTIMERIZATION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; VIROLOGY;

HEPATITIS C VIRUS;

ANIMALS; CELL LINE; DEAD-BOX RNA HELICASES; GENE EXPRESSION; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON REGULATORY FACTOR-3; INTERFERON-ALPHA; INTERFERON-BETA; MICE; PROTEIN BIOSYNTHESIS; PROTEIN MULTIMERIZATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 80053174470     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-445     Document Type: Article

References (40)

1. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Alter HJ, Seeff LB, Semin Liver Dis 2000 20 17 35 10.1055/s-2000-9505 10895429 (Pubitemid 30421406)
2. Recommendation for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention, MMWR Recomm 1998 41 39 Rep 47
3. The economics of hepatitis C virus. Shah BB, Wong JB, Clin Liver Dis 2006 10 717 734 10.1016/j.cld.2006.08.026 17164114 (Pubitemid 44895435)
4. A Toll-like receptor recognizes bacterial DNA. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S, Nature 2000 408 740 745 10.1038/35047123 11130078 (Pubitemid 32015992)
5. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA, Nature 2001 413 732 738 10.1038/35099560 11607032 (Pubitemid 33009951)
6. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C, Science 2004 303 1529 1531 10.1126/science.1093616 14976261 (Pubitemid 38314425)
7. The interferon inducing pathways and the hepatitis C virus. Meurs EF, Breiman A, World J Gastroenterol 2007 13 2446 2454 17552028 (Pubitemid 46929500)
8. Cell type specific involvement of RIG-I in antiviral responses. Kato H, Takeuchi O, Akira S, Nippon Rinsho 2006 64 1244 1247 16838639
9. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr, Nature 2008 454 523 527 10.1038/nature07106 18548002
10. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T, Nature 2005 434 772 777 10.1038/nature03464 15800576 (Pubitemid 44739521)
11. Antiviral innate immunity pathways. Seth RB, Sun L, Chen ZJ, Cell Res 2006 16 141 147 10.1038/sj.cr.7310019 16474426 (Pubitemid 43247969)
12. Mechanism of the interferon alpha response against hepatitis C virus replicons. Guo JT, Sohn JA, Zhu Q, Seeger C, Virology 2004 325 71 81 10.1016/j.virol.2004.04.031 15231387 (Pubitemid 38844771)
13. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. Wang C, Pflugheber J, Sumpter R Jr, Sodora DL, Hui D, Sen GC, Gale M Jr, J Virol 2003 77 3898 3912 10.1128/JVI.77.7.3898-3912.2003 12634350 (Pubitemid 36350931)
14. Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo. Takemoto Y, Yano H, Momosaki S, Ogasawara S, Nishida N, Kojiro S, Kamura T, Kojiro M, Clin Cancer Res 2004 10 7418 7426 10.1158/1078-0432.CCR-04-0279 15534119 (Pubitemid 39487731)
15. IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. Pletneva M, Fan H, Park JJ, Radojcic V, Jie C, Yu Y, Chan C, Redwood A, Pardoll D, Housseau F, Cancer Res 2009 69 6607 6614 10.1158/0008-5472.CAN-09-0508 19679552
16. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Biron CA, Semin Immunol 1998 10 383 390 10.1006/smim.1998.0138 9799713 (Pubitemid 28499552)
17. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR, Hepatology 52 1581 1589
18. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, Rotman Y, Ghany MG, Hoofnagle JH, Liang TJ, Heller T, Rehermann B, Gastroenterology 2010 138 1 325 35 10.1053/j.gastro.2009.08.066 19747917
19. Understanding hepatitis C. McHutchison JG, Am J Manag Care 2004 10 21 29 15084064
20. Analysis of successful immune responses in persons infected with hepatitis C virus. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD, J Exp Med 2000 191 1499 1512 10.1084/jem.191.9.1499 10790425 (Pubitemid 30257347)
21. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. Sumpter R Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M Jr, J Virol 2005 79 2689 2699 10.1128/JVI.79.5.2689-2699.2005 15708988 (Pubitemid 40270547)
22. Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J, Biochem Pharmacol 2006 72 1469 1476 10.1016/j.bcp.2006.06.002 16846591 (Pubitemid 44666732)
23. STAT3 induces anti-hepatitis C viral activity in liver cells. Zhu H, Shang X, Terada N, Liu C, Biochem Biophys Res Commun 2004 324 518 528 10.1016/j.bbrc.2004.09.081 15474458 (Pubitemid 39345548)
24. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, et al. Nat Med 2005 11 791 796 10.1038/nm1268 15951748 (Pubitemid 41021213)
25. Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. Honda M, Kaneko S, Matsushita E, Kobayashi K, Abell GA, Lemon SM, Gastroenterology 2000 118 152 162 10.1016/S0016-5085(00)70424-0 10611164 (Pubitemid 30020383)
26. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. Blight KJ, McKeating JA, Rice CM, J Virol 2002 76 13001 13014 10.1128/JVI.76.24.13001-13014.2002 12438626 (Pubitemid 35386984)
27. Identification of IFITM3 gene to inhibit hepatitis C viral translation in a stable STAT1 cell line. Yao L, Xiaoyu Li, Journal of Viral hepatitis 2011 18 1 523 e529 10.1111/j.1365-2893.2011.01452.x 21914072
28. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford JM, Nelson DR, Liu C, Gastroenterology 2007 133 1649 1659 10.1053/j.gastro.2007.09.017 17983809 (Pubitemid 350029762)
29. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. Matsuda T, Nakamura T, Nakao K, Arai T, Katsuki M, Heike T, Yokota T, Embo J 1999 18 4261 4269 10.1093/emboj/18.15.4261 10428964 (Pubitemid 29364128)
30. Viruses and interferon: a fight for supremacy. Katze MG, He Y, Gale M Jr, Nat Rev Immunol 2002 2 675 687 10.1038/nri888 12209136 (Pubitemid 37328725)
31. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Thompson AJ, Locarnini SA, Immunol Cell Biol 2007 85 435 445 10.1038/sj.icb.7100100 17667934 (Pubitemid 47367510)
32. Reduced antigen concentration and costimulatory blockade increase IFN-gamma secretion in naive CD8+ T cells. Hall HT, Petrovic J, Hoglund P, Eur J Immunol 2004 34 3091 3101 10.1002/eji.200425074 15384046 (Pubitemid 39549388)
33. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, Nakaya T, Katsuki M, Noguchi S, Tanaka N, Taniguchi T, Immunity 2000 13 539 548 10.1016/S1074-7613(00)00053-4 11070172
34. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Au WC, Moore PA, Lowther W, Juang YT, Pitha PM, Proc Natl Acad Sci USA 1995 92 11657 11661 10.1073/pnas.92.25.11657 8524823 (Pubitemid 26014172)
35. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, Randall RE, Proc Natl Acad Sci USA 2004 101 17264 17269 10.1073/pnas.0407639101 15563593 (Pubitemid 39627808)
36. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Honda M, Kaneko S, Shimazaki T, Matsushita E, Kobayashi K, Ping LH, Zhang HC, Lemon SM, Hepatology 2000 31 1351 1359 10.1053/jhep.2000.7985 10827163 (Pubitemid 30351299)
37. Regulated nuclear-cytoplasmic localization of interferon regulatory factor 3, a subunit of double-stranded RNA-activated factor 1. Kumar KP, McBride KM, Weaver BK, Dingwall C, Reich NC, Mol Cell Biol 2000 20 4159 4168 10.1128/MCB.20.11.4159-4168.2000 10805757 (Pubitemid 30314513)
38. Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Dash S, Prabhu R, Hazari S, Bastian F, Garry R, Zou W, Haque S, Joshi V, Regenstein FG, Thung SN, Liver Int 2005 25 580 594 10.1111/j.1478-3231.2005.01082.x 15910496 (Pubitemid 40861908)
39. Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes. Hazari S, Patil A, Joshi V, Sullivan DE, Fermin CD, Garry RF, Elliott RM, Dash S, J Gen Virol 2005 86 3047 3053 10.1099/vir.0.81132-0 16227227 (Pubitemid 41555570)
40. Correlation between translation efficiency and outcome of combination therapy in chronic hepatitis C genotype 3. Yasmeen A, Hamid S, Granath FN, Lindstrom H, Elliott RM, Siddiqui AA, Persson MA, J Viral Hepat 2006 13 87 95 10.1111/j.1365-2893.2005.00660.x 16436126